Comprehensive molecular screening: from the RT-PCR to the RNA-seq

Area of Science:

• Molecular Biology
• Genomics
• Cancer Research

Background:

• Reverse Transcription quantitative Polymerase Chain Reaction (RT-PCR) is the gold standard for mRNA expression analysis, crucial for patient stratification and outcome prediction in various diseases.
• RT-PCR's limitations include inherent data variability, time-consuming laboratory processes, and difficulties in cross-experiment comparisons, hindering widespread clinical application.
• Existing techniques have not fully addressed the need for efficient and reproducible transcriptome analysis in clinical settings.

Purpose of the Study:

• To introduce RNA sequencing (RNA-seq) as a novel, effective method for transcriptome composition analysis and the discovery of novel transcripts.
• To highlight the advantages of RNA-seq, including high reproducibility, broad dynamic range, reduced sample requirements, and the ability to detect novel transcripts and alternative splicing.
• To propose RNA-seq as a complementary technology to RT-PCR for enhanced cancer patient characterization and clinical decision-making.

Main Methods:

• Comparison of RNA sequencing (RNA-seq) with traditional Reverse Transcription quantitative Polymerase Chain Reaction (RT-PCR) for mRNA expression analysis.
• Evaluation of RNA-seq's capabilities in transcriptome profiling, including novel exon and gene discovery, and detection of alternative splicing.
• Assessment of the potential clinical utility of integrating RNA-seq and RT-PCR in routine cancer diagnostics.

Main Results:

• RNA-seq provides high reproducibility, a large dynamic range, and requires less RNA sample compared to RT-PCR.
• RNA-seq can detect novel transcripts and alternative splicing, even without a reference genome.
• RNA-seq is unlikely to replace RT-PCR but will serve as a valuable complementary tool, identifying genes for subsequent RT-PCR validation.

Conclusions:

• The combined application of RNA-seq and RT-PCR offers a powerful approach for comprehensive tumor molecular characterization.
• Integrating these complementary technologies can significantly aid oncologists in making informed clinical decisions for cancer patients.
• RNA-seq enhances the ability to identify all molecular characteristics of a tumor, improving patient management.